ARTICLE SUMMARY:
The pace of medical device innovation for diseases of the deep veins is accelerating. Strategics and start-ups alike hope to create solutions for underserved patients while grabbing a share of an unpenetrated $6 billion market. Part 1 of a 2-part review of the venous device market.
Maybe it’s the “Inari Effect” or simply an inflection point in the evolution of the youngest interventional specialty in vascular disease, but the profile of device innovation in deep venous diseases seems to be rising every day. New companies are attracting sterling investors, like Akura Medical, a second-generation venous thrombectomy company, which raised a $35 million Series B round in October 2023, and Endovascular Engineering, which, also developing a next-gen venous thrombectomy product, raised a Series A round in 2022, boasting Santé Ventures, Cordis, and a second unnamed strategic investor among its roster of investors. Noted one medical device CEO we spoke with recently, “Nearly every garage in Silicon Valley has at least one venous thrombectomy project going on.” And most of the major companies operating in coronary intervention have established a presence here by acquisition or internal development.
As to the “Inari Effect,” Inari Medical was the first company to become a fully-fledged pure play focusing on deep venous diseases with devices purposely built for the way veins are different than arteries.
